Product Information for the User
Olanzapina Teva 2.5 mg Film-Coated Tablets
Olanzapina Teva 5 mg Film-Coated Tablets
Olanzapina Teva 7.5 mg Film-Coated Tablets
Olanzapina Teva 10 mg Film-Coated Tablets
Olanzapina Teva 15 mg Film-Coated Tablets
Olanzapina Teva 20 mg Film-Coated Tablets
olanzapina
Read this entire leaflet carefully before you start taking this medicine because it contains important information for you.
Olanzapina Teva contains the active ingredient Olanzapina. Olanzapina Teva belongs to a group of medicines called antipsychotics and is indicated for the treatment of the following diseases.
Olanzapina Teva has shown that it can prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapina.
Do not take Olanzapina Teva
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olanzapina Teva.
If you have any of the following conditions, inform your doctor as soon as possible:
If you have dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or lack of blood flow to the brain.
As a routine precaution, if you are over 65 years old, your doctor should monitor your blood pressure.
Children and adolescents
Patients under 18 years old should not take Olanzapina Teva.
Other medications and Olanzapina Teva
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Only use other medicines at the same time as Olanzapina Teva if your doctor authorizes it. You may feel drowsy if you combine Olanzapina Teva with antidepressants or medications for anxiety or sleep (tranquilizers).
Specifically, tell your doctor if you are taking:
Use of Olanzapina Teva with alcohol
You should not drink alcohol while taking Olanzapina Teva, as it may cause drowsiness when combined with alcohol.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor before using this medication.
You should not take this medication while breastfeeding, as small amounts of Olanzapina Teva may pass into breast milk.
The following symptoms may occur in newborns of mothers who used Olanzapina Teva in the last trimester (last three months of pregnancy): tremors, muscle stiffness, and/or weakness, drowsiness, agitation, respiratory problems, and difficulty feeding. If your baby experiences any of these symptoms, contact your doctor.
Driving and operating machinery
There is a risk of drowsiness when taking Olanzapina Teva. If this happens, do not drive vehicles or operate machinery. Consult your doctor.
Olanzapina Teva contains lactose
If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Your doctor will tell you how many tablets of Olanzapina Teva to take and for how long. The daily dose of Olanzapina Teva ranges from 5 mg to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking Olanzapina Teva unless your doctor tells you to.
You should take your Olanzapina Teva tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. You can take them with or without food. Olanzapina Teva tablets are for oral administration. Swallow the Olanzapina Teva tablets whole with water.
If you take more Olanzapina Teva than you should
Patients who have taken more Olanzapina Teva than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue) and reduced consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle rigidity, drowsiness or lethargy, slowed respiratory frequency, aspiration, increased or decreased blood pressure, abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you notice any of the mentioned symptoms. Show the packaging with the tablets to the doctor.
If you forget to take Olanzapina Teva
Take your tablet as soon as you remember. Do not take a double dose to make up for the missed dose.
If you interrupt treatment with Olanzapina Teva
Do not stop treatment simply because you feel better. It is very important that you continue taking Olanzapina Teva as long as your doctor tells you to.
If you stop taking Olanzapina Teva suddenly, you may experience symptoms such as sweating, inability to sleep, tremors, anxiety, nausea, and vomiting. Your doctor may suggest that you gradually reduce the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Immediately contact your doctor if you have:
Frequent side effects (which can affect more than 1 in 10 people) include weight gain, drowsiness, and increased levels of prolactin in the blood. In the early stages of treatment, some people may feel dizzy or faint (with slower heartbeats), especially when getting up from lying down or sitting. This sensation usually disappears spontaneously, but if it does not, consult your doctor.
Common side effects (which can affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating lipids, and at the beginning of treatment, temporary increases in liver enzymes, increased levels of blood sugar and urine; increased levels of uric acid and creatine phosphokinase in the blood: increased appetite: dizziness; agitation; tremor; strange movements (dyskinesia); constipation; dry mouth; skin rash; loss of strength; excessive fatigue, fluid retention causing inflammation of the hands, ankles, or feet: fever; joint pain and sexual dysfunction such as decreased libido in men.
Rare side effects (which can affect up to 1 in 100 people) include hypersensitivity (e.g. inflammation of the mouth and throat, itching, skin rash); diabetes or worsening of diabetes, occasionally related to ketoacidosis (acetone in the blood and urine) or coma; seizures, in most cases related to a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; speech problems; stuttering; slow pulse; sensitivity to sunlight; nasal bleeding; abdominal distension; excessive salivation; memory loss or forgetfulness; urinary incontinence; loss of ability to urinate; hair loss; absence or decrease of menstrual periods; and changes in the breast gland in men and women such as abnormal milk production or abnormal growth.
Rare side effects (which can affect up to 1 in 1000 people) include a decrease in normal body temperature; abnormal heart rhythm, sudden death without apparent explanation; blood clots such as deep vein thrombosis in the legs and blood clots in the lung; pancreatitis, which causes severe stomach pain, fever, and discomfort; liver disease, with yellowing of the skin and white areas of the eye; muscle disorder presenting as unexplained pain; and prolonged and/or painful erection.
Severe allergic reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. DRESS initially presents with symptoms similar to the flu, with skin rash on the face that spreads to other areas, fever, lymph node swelling, elevated liver enzymes in blood tests, and increased levels of a type of white blood cell (eosinophilia).
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, increased body temperature, skin redness, and difficulty walking. Some deaths have been reported in this particular group of patients.
Olanzapine Teva may worsen symptoms in patients with Parkinson's disease.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the carton box after “EXP”. The expiration date is the last day of the month indicated.
Store below 25°C. Store in the original packaging to protect it from light.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medication that you no longer need. This will help protect the environment.
Composition of Olanzapina Teva
Each film-coated tablet of Olanzapina Teva 2.5 mg contains 2.5 mg of active ingredient.
Each film-coated tablet of Olanzapina Teva 5 mg contains 5 mg of active ingredient.
Each film-coated tablet of Olanzapina Teva 7.5 mg contains 7.5 mg of active ingredient.
Each film-coated tablet of Olanzapina Teva 10 mg contains 10 mg of active ingredient.
Each film-coated tablet of Olanzapina Teva 15 mg contains 15 mg of active ingredient.
Each film-coated tablet of Olanzapina Teva 20 mg contains 20 mg of active ingredient.
Core tablet:lactose monohydrate, hydroxypropylcellulose, crospovidone (type A), anhydrous colloidal silica, microcrystalline cellulose, magnesium stearate.
Tablet coating:hypromellose, polydextrose, triacetin, macrogol 8000, titanium dioxide (E171). In addition, the 15 mg dose contains indigo carmine (E132) and the 20 mg dose contains iron oxide red (E172).
Appearance of the product and contents of the package
The film-coated tablets of Olanzapina Teva 2.5 mg are film-coated, white, biconvex, round, and have "OL 2.5" engraved on one side and are smooth on the other.
The film-coated tablets of Olanzapina Teva 5 mg are film-coated, white, biconvex, round, and have "OL 5" engraved on one side and are smooth on the other.
The film-coated tablets of Olanzapina Teva 7.5 mg are film-coated, white, biconvex, round, and have "OL 7.5" engraved on one side and are smooth on the other.
The film-coated tablets of Olanzapina Teva 10 mg are film-coated, white, biconvex, round, and have "OL 10" engraved on one side and are smooth on the other.
The film-coated tablets of Olanzapina Teva 15 mg are film-coated, light blue, biconvex, oval, and have "OL 15" engraved on one side and are smooth on the other.
The film-coated tablets of Olanzapina Teva 20 mg are film-coated, pink, biconvex, oval, and have "OL 20" engraved on one side and are smooth on the other.
Olanzapina Teva 2.5 mg film-coated tablets are presented in cartons of 28, 30, 35, 56, 70, or 98 film-coated tablets.
Olanzapina Teva 5 mg film-coated tablets are presented in packs of 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 70, 70 x 1, 98, or 98 x 1 film-coated tablets.
Olanzapina Teva 7.5 mg film-coated tablets are presented in packs of 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98, or 98 x 1 film-coated tablets.
Olanzapina Teva 10 mg film-coated tablets are presented in packs of 7, 7 x 1, 28, 28 x 1, 30, 30 x 1, 35, 35 x 1, 50, 50 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98, or 98 x 1 film-coated tablets.
Olanzapina Teva 15 mg film-coated tablets are presented in packs of 28, 30, 35, 50, 56, 70, or 98 film-coated tablets.
Olanzapina Teva 20 mg film-coated tablets are presented in packs of 28, 30, 35, 56, 70, or 98 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Teva B.V.
Swensweg 5 2
031GA Haarlem
Netherlands
Manufacturer
Teva Pharmaceutical Works Co. Ltd
Pallagi út 13
4042 Debrecen
Hungary
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A. /AG Tel/Tél: +32 3 820 73 73 | Lietuva UAB Teva Baltics Tel: +370 5 266 02 03 |
Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien Tél/Tel: +32 38207373 | |
Ceská republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Magyarország Teva Gyógyszergyár Zrt. Tel: (+36) 1 288 6400 |
Danmark SanoSwiss UAB Litauen Tlf.: +370 70001320 | Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 (0) 207 540 7117 |
Deutschland TEVA GmbH +49 731 40 208 | Nederland Teva Nederland B.V. Tel: +31 800 0228 400 |
Eesti UAB Teva Baltics Eesti filiaal Tel.: +372 6610801 | Norge Teva Norway AS Tlf: +47 66 77 55 90 |
Εlláδα TEVA HELLAS A.E. Τηλ: +30 2118805000 | Österreich Ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
España Teva Pharma, S.L.U. Tel.: + 34 91 387 32 80 | Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel.: +48 22 345 93 00 |
France Teva Santé Tél: +33 1 55 91 78 00 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda Tel: +351 21 476 75 50 |
Hrvatska Pliva Hrvatska d.o.o Tel: + 385 1 37 20 000 | România Teva Pharmaceuticals S.R.L Tel: +40 21 230 65 24 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 (0) 207 540 7117 | Slovenija Pliva Ljubljana d.o.o. Tel: +386 158 90 390 |
Ísland Teva Pharma Iceland ehf. Sími: + 354 550 3300 | Slovenská republika TEVA Pharmaceuticals Slovakia s.r.o Telephone: +421257267911 |
Italia Teva Italia S.r.l Tel:. +39 028917981 | Suomi/Finland Teva Finland Oy Puh/Tel: +358 20 180 5900 |
Κúpρος TEVA HELLAS A.E. Εlláδα Τηλ: +30 2118805000 | Sverige Teva Sweden AB Tel: +46 (0)42 12 11 00 |
Latvija UAB Teva Baltics filiale Latvija Tel: +371 67 323 666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 207 540 7117 |
Date of the last revision of this leaflet: <{MM/AAAA}><{month AAAA}>.
More detailed information about this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.